Abcuro
PrivateLast Round
Series D
Aug 13, 2026
Total Funding Raised
$407.25M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Abcuro is a biotechnology company that develops immunomodulatory therapeutics aimed at treating autoimmunity and cancer through innovative analysis of transcription data to target critical immune system components.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Abcuro Comparables
Compare Abcuro with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| HiFiBiO Therapeutics | 86% | |
| Dren Bio | 79% | |
| Santa Ana Bio | 72% |
Abcuro Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Aug 13, 2026 | ||||
| Series C | Feb 12, 2025 | ||||
| Series B | Aug 17, 2023 | ||||
| Series A Extension | Jan 7, 2021 | ||||
| Series A | Nov 9, 2018 | ||||
Seed | Dec 13, 2016 |
Key People
Founding team and executive leadership
Abcuro Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series C, Series D, Series B |
| Soleus Capital | Series D, Series C, Series B |
| Bain Capital Life Sciences | Series D, Series C, Series B |
| RA Capital Management | Series D, Series C, Series A Extension, Series B |
| New Leaf Venture Partners | Series C, Series B, Series D |
| New Enterprise Associates | Series D, Series C |
| Kaitai Capital | Series D, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors grew 59% MoM, reaching 3.9K.
- Aug 13, 2026
Raised $39.4M in early stage VC funding.
Recent news
Latest coverage and updates
- goes_publicSep 8, 2026
Abcuro is planning to go public.
- launchesAug 20, 2026
Abcuro launched Phase 3 trial of ulviprubart on Aug 1st '26.
- receives_financingAug 19, 2026
Abcuro receives $66M Series D financing in Massachusetts on Aug 18th '26
Abcuro Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Abcuro's valuation, stock price, and market status.
Is Abcuro a public or private company?
Abcuro is a private company.
What is the current stock price of Abcuro?
Abcuro is a private company, so its shares have no public market price. Caplight tracks Abcuro's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Abcuro worth (valuation)?
Valuation information for Abcuro is not publicly available.
Can I buy Abcuro stock?
Abcuro shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Abcuro's last funding round?
Abcuro's most recent funding round was Series D on August 13, 2026.
Who are the main investors in Abcuro?
Key investors in Abcuro include Redmile Group, Bain Capital Life Sciences, New Leaf Venture Partners, New Enterprise Associates, Kaitai Capital.
Will Abcuro IPO soon?
No public IPO plans have been announced for Abcuro.
How can I track Abcuro secondary market activity?
Caplight tracks bids, offers, and trades in Abcuro's shares on secondary markets.